MX2018014938A - Combinaciones farmaceuticas para el tratamiento del cancer. - Google Patents

Combinaciones farmaceuticas para el tratamiento del cancer.

Info

Publication number
MX2018014938A
MX2018014938A MX2018014938A MX2018014938A MX2018014938A MX 2018014938 A MX2018014938 A MX 2018014938A MX 2018014938 A MX2018014938 A MX 2018014938A MX 2018014938 A MX2018014938 A MX 2018014938A MX 2018014938 A MX2018014938 A MX 2018014938A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combinations
treating cancer
cancer
pharmaceutical
combinations
Prior art date
Application number
MX2018014938A
Other languages
English (en)
Inventor
Bausch Alexander
Original Assignee
Support Venture Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Support Venture Gmbh filed Critical Support Venture Gmbh
Publication of MX2018014938A publication Critical patent/MX2018014938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a combinaciones farmacéuticas que comprenden un agonista de PPAR y un inhibidor de P38 para usar en un método para la prevención, el retraso de la progresión o el tratamiento del cáncer.
MX2018014938A 2016-06-08 2017-06-06 Combinaciones farmaceuticas para el tratamiento del cancer. MX2018014938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16173443 2016-06-08
PCT/EP2017/063714 WO2017211830A1 (en) 2016-06-08 2017-06-06 Pharmaceutical combinations for treating cancer

Publications (1)

Publication Number Publication Date
MX2018014938A true MX2018014938A (es) 2019-05-16

Family

ID=56132777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014938A MX2018014938A (es) 2016-06-08 2017-06-06 Combinaciones farmaceuticas para el tratamiento del cancer.

Country Status (26)

Country Link
US (2) US11285155B2 (es)
EP (1) EP3468604B1 (es)
JP (2) JP7349790B2 (es)
KR (1) KR102437685B1 (es)
CN (2) CN109414506B (es)
AU (1) AU2017277478B2 (es)
BR (1) BR112018075135A2 (es)
CA (1) CA3023392C (es)
CL (1) CL2018003509A1 (es)
CO (1) CO2018013020A2 (es)
CY (1) CY1124123T1 (es)
DK (1) DK3468604T3 (es)
EA (1) EA201892287A1 (es)
ES (1) ES2866883T3 (es)
HU (1) HUE053648T2 (es)
IL (1) IL263407B (es)
MX (1) MX2018014938A (es)
MY (1) MY195671A (es)
PE (1) PE20190376A1 (es)
PH (1) PH12018550186A1 (es)
PL (1) PL3468604T3 (es)
PT (1) PT3468604T (es)
SG (1) SG11201809882XA (es)
UA (1) UA123914C2 (es)
WO (1) WO2017211830A1 (es)
ZA (1) ZA201900052B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507914A (ja) 2015-03-09 2018-03-22 インテクリン・セラピューティクス・インコーポレイテッド 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
CA3033887A1 (en) * 2016-08-17 2018-02-22 Support-Venture Gmbh Method of preventing or treating hearing loss
EA201990512A1 (ru) * 2016-08-18 2019-08-30 Интекрин Терапьютикс, Инк. АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ
BR112019020485A2 (pt) 2017-04-03 2020-05-12 Coherus Biosciences, Inc. Agonista ppary para tratamento de paralisia supranuclear progressiva
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
US20210267983A1 (en) * 2018-07-13 2021-09-02 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
PL366918A1 (en) * 2001-02-12 2005-02-07 F.Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
US6852141B2 (en) * 2001-06-06 2005-02-08 Donaldson Company, Inc. Filter element having center piece and methods
CN1771034A (zh) * 2002-01-14 2006-05-10 法马西亚公司 过氧化物酶体增殖物激活受体－α激动剂和环加氧酶－2选择性抑制剂的组合及其治疗用途
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
PL1685131T3 (pl) 2003-11-13 2007-08-31 Hoffmann La Roche Hydroksyalkilo-podstawione pirydo-7-pirymidyn-7-ony
WO2006127678A2 (en) * 2005-05-23 2006-11-30 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
WO2007146712A2 (en) * 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
EP2158182A2 (en) 2007-06-15 2010-03-03 F. Hoffmann-Roche AG A novel process for the preparation of 3-amino-pentan-1,5-diol
WO2010071583A1 (en) * 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
CA2789847A1 (en) * 2010-02-15 2011-08-18 Synovo Gmbh Kinase modulators for the treatment of cancer

Also Published As

Publication number Publication date
KR20190017756A (ko) 2019-02-20
IL263407A (en) 2018-12-31
DK3468604T3 (da) 2021-04-19
JP2022046526A (ja) 2022-03-23
ZA201900052B (en) 2021-10-27
CL2018003509A1 (es) 2019-03-15
KR102437685B1 (ko) 2022-08-29
MY195671A (en) 2023-02-03
AU2017277478A1 (en) 2018-11-22
PL3468604T3 (pl) 2021-07-12
CN109414506A (zh) 2019-03-01
AU2017277478B2 (en) 2023-03-16
SG11201809882XA (en) 2018-12-28
US20220175786A1 (en) 2022-06-09
ES2866883T3 (es) 2021-10-20
PH12018550186A1 (en) 2019-03-18
US20190160072A1 (en) 2019-05-30
HUE053648T2 (hu) 2021-07-28
US11285155B2 (en) 2022-03-29
CY1124123T1 (el) 2022-05-27
CN115105601A (zh) 2022-09-27
PT3468604T (pt) 2021-04-06
CA3023392C (en) 2024-02-06
CN109414506B (zh) 2022-06-03
EA201892287A1 (ru) 2019-06-28
EP3468604A1 (en) 2019-04-17
JP7349790B2 (ja) 2023-09-25
WO2017211830A1 (en) 2017-12-14
EP3468604B1 (en) 2021-01-20
BR112018075135A2 (pt) 2019-03-26
JP2019517562A (ja) 2019-06-24
CA3023392A1 (en) 2017-12-14
CO2018013020A2 (es) 2018-12-28
UA123914C2 (uk) 2021-06-23
PE20190376A1 (es) 2019-03-08
IL263407B (en) 2021-09-30

Similar Documents

Publication Publication Date Title
PH12018550186A1 (en) Pharmaceutical combinations for treating cancer
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
GB2541571A (en) Pharmaceutical compositions
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
IL271728A (en) Materials, uses and treatment methods
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PH12016501838A1 (en) Compounds and their methods of use
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
IL251881A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
MX2019010060A (es) Composiciones y metodo para tratar cancer.
EP3318659A4 (en) SURFACE TREATMENT AGENT, SURFACE TREATMENT METHOD, AND SURFACE-TREATED METALLIC MATERIAL
ZA201904626B (en) Cancer treatment method and composition
ZA201904328B (en) Composition, application thereof and treatment method
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
PL3481194T3 (pl) Wodne kompozycje do zaprawiania nasion, zaprawione nimi nasiona i sposoby zaprawiania nasion
MX2018010919A (es) Procedimiento para el tratamiento termico de un producto plano de acero, producto plano de acero tratado termicamente asi como su uso.
MA40574A (fr) Traitement de maladies fibrotiques
MX2019003002A (es) Terapias de combinacion que usan derivados de indazolilbenzamida para el tratamiento del cancer.
MX2018013863A (es) Terapias combinadas que usan derivados de indazolilbenzamida para el tratamiento del cancer.
MX2017014893A (es) Composicion herbal para el tratamiento del dolor de espalda.